Tumor combination therapy and methods of use

By combining pravabulin and the CDK inhibitor abexib, and optimizing the route of administration and dosage, the problems of low response rate and drug resistance of CDK inhibitor therapy were solved, resulting in more efficient breast cancer treatment.

CN121311228APending Publication Date: 2026-01-09DALIAN WANCHUN BULIN PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202480037116.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-20
Publication Date
2026-01-09

Smart Images

  • Figure CN121311228A_ABST
    Figure CN121311228A_ABST
Patent Text Reader

Abstract

Disclosed herein are methods of treating cancer by administering plinabulin and a cyclin-dependent kinase inhibitor, such as abamecril, in combination.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

    US7064201B2

  • Analogs of dehydrophenylahistins and their therapeutic use

    US7919497B2